Concepedia

RETRACTED: Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

Seibu Mochizuki, Björn Dahlöf, Mitsuyuki Shimizu, Katsunori Ikewaki, Makoto Yoshikawa, Ikuo Taniguchi, Makoto Ohta, Taku Yamada, Kazuhiko Ogawa, Kiyoshi Kanae,

The Lancet · 2007 · 348 citations · 30 references

DOIFull text

Open access

Concepts

References

30

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw et al. · New England Journal of Medicine · 2001 · 7.5K citations · Full text

, , +17

Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes

Edmund J. Lewis, Lawrence G. Hunsicker, William R. Clarke et al. · New England Journal of Medicine · 2001 · 6K citations · Full text

, , +16

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Björn Dahlöf, Richard B. Devereux, Sverre E. Kjeldsen et al. · The Lancet · 2002 · 5.4K citations

, , +13

A Multiple Testing Procedure for Clinical Trials

Peter C. O’Brien, Thomas R. Fleming · Biometrics · 1979 · 3.3K citations

, , +13

A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

Jay N. Cohn, Gianni Tognoni · New England Journal of Medicine · 2001 · 3.1K citations · Full text

, , +13